PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Slides:

Advertisements

Similar presentations

Enhanced Sensitivity to Sunitinib by Inhibition of Akt1 Expression in Human Castration- resistant Prostate Cancer PC3 Cells Both In Vitro and In Vivo

Advertisements

A Novel Cinnamide YLT26 Induces Breast Cancer Cells Apoptosis via ROS-Mitochondrial Apoptotic Pathway in Vitro and Inhibits.

Cantharidin Inhibits the Growth of Triple-Negative Breast Cancer Cells by Suppressing Autophagy and Inducing Apoptosis in Vitro and in.

A, Effect of folate-FITC (500 nmol/kg, 5 days/week) and/or sunitinib (20 mg/kg daily) therapy on the growth of M109 tumors in Balb/c mice. A, Effect of.

SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models. SCC244 significantly inhibited c-Met–driven tumor growth in cancer CDX models.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis Dao M Nguyen, MD, Dominique.

Pegylated arginase I: a potential therapeutic approach in T-ALL

Volume 191, Issue 1, Pages (January 2014)

by Jun Yuan, David B. Lovejoy, and Des R. Richardson

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non–small cell lung cancer in vitro and in vivo

RORα inhibits cell proliferation and expression of the E2F1-targeted genes. RORα inhibits cell proliferation and expression of the E2F1-targeted genes.

Effects of SC144 on in vivo ovarian tumor.

DQ661 improves survival in colon cancer model and potentiates activity of gemcitabine in KPC pancreatic cancer syngeneic model. DQ661 improves survival.

Level of EGFR inhibition determines cell death response in EGFR mutant GBM cells. Level of EGFR inhibition determines cell death response in EGFR mutant.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Hsp90 Inhibition Overcomes HGF-Triggering Resistance to EGFR-TKIs in EGFR-Mutant Lung Cancer by Decreasing Client Protein Expression and Angiogenesis

Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models Josephine Hai, PhD, Shingo Sakashita,

Volume 82, Issue 9, Pages (November 2012)

miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK

NrasG12D induces CNS tumors in mice.

Molecular Therapy - Nucleic Acids

Overexpression of HGF decreases MET protein levels.

Activity of MAC-321 (i. v. and p. o

Effect of MI-773 dosing on long-term efficacy.

Rapamycin inhibits KGF-induced mortality, proliferation, cytokine expression, and susceptibility to IAV infection, in vivo. Rapamycin inhibits KGF-induced.

Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal tumors. Effect of mitomycin C and bortezomib on the growth of LS174T intraperitoneal.

Fig. 6 RUNX/CBFB interaction inhibitor, Ro5-3335, significantly decreases mouse neurofibroma growth in vivo. RUNX/CBFB interaction inhibitor, Ro5-3335,

TFAP2A knockdown inhibits tumor growth in vivo.

PTENP1 serves as a ceRNA in the regulation of tumor growth in RCC

Effect of HA on hematopoietic recovery in tumor-bearing mice.

PTENP1 sensitizes renal cancer cells to chemotherapy.

A, chemical structures of PRIMA-1 and PRIMA-1Met.

coTCRcys-transduced T cells control tumor growth in vivo.

Accelerated metastasis spread in tumor-bearing mice treated with paclitaxel and anakinra. Accelerated metastasis spread in tumor-bearing mice treated with.

Quercetin induces apoptosis in P39 xenografts.

The effect of IAA on tumor growth in an SK-MEL-28 xenograft model.

Antitumor activity of MLN8237 against TNBC patient-derived tumor xenografts (PDTX) in vivo. Antitumor activity of MLN8237 against TNBC patient-derived.

Cisplatin plus PTUPB decreases proliferation and angiogenesis but increases apoptosis as determined by immunohistochemical (IHC) analysis. Cisplatin plus.

PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. PVHA increased anti-PD-L1–mediated growth inhibition in 4T1/HAS3 tumors. A, 4T1/HAS3.

Angiogenesis in tumors formed by cells varying in the expression of CXCR2. Angiogenesis in tumors formed by cells varying in the expression of CXCR2. A,

5FU-induced specific activation of CD8+ T cells.

N-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. n-3 PUFAs promote endometrial cancer cell apoptosis in vitro and in vivo. HEC-1-A.

Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth and metastasis. Paclitaxel treatment along with CXCR2 knockdown reduces tumor growth.

Antitumor effects of celastrol in vitro and in vivo.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

Pharmacodynamic evaluation of VT-464 and ABI in MR49F xenograft model.

Effect of the crystal form and solid dispersion preparations of KRN633 on the growth of human tumor xenografts in mice. Effect of the crystal form and.

A, tumor growth studies in H1975 tumor–bearing mice.

CRA inhibits the growth of human tumor xenografts in vivo.

NT157 treatment inhibits LNCaP xenograft growth and delays castration-resistant progression. NT157 treatment inhibits LNCaP xenograft growth and delays.

Effect of CDV on human SF7796 xenografts in vivo.

Impact of eNOS expression and treatment with GSNO on prostate tumor growth. Impact of eNOS expression and treatment with GSNO on prostate tumor growth.

Comparison of in vivo activity of 4D5scFvZZ and 4D5scFv.

SW620 xenografts treated with combination siKRAS+siPIK3CA/B.

Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors. Efficacy of KM100 and/or MTX in BALB/c mice bearing subcutaneous TUBO tumors.

Increased accumulation of pmel-1 T cells to tumor sites and enhanced antitumor immune response in mice receiving ACT combined with anti-PD-1 antibody treatment.

Proliferation of TA3-Ha and TA3-St cells in vitro and in vivo.

BMX is a driver of castration resistance in vitro and in vivo.

A, antitumor activity of temozolomide (30 mg/kg for 5 days), talazoparib (0.25 mg/kg twice daily for 5 days), or in combination against “sensitive” Ewing.

Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC xenografts. Ganetespib suppresses tumor growth and extends survival in ALK+ NSCLC.

Inhibition of spontaneous pulmonary metastasis and prolonged survival after removal of primary tumor and intratracheal delivery of rAAV2/5-VAS. Inhibition.

GCS-100 selectively kills KRAS-addicted lung tumors.

Fig. 6. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex vivo. Combinatorial VCPI and OV M1 treatment is efficacious in vivo and ex.

Molecular Therapy - Nucleic Acids

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

AXL knockout does not prevent dormancy.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. SCID mice (n = 5/group) were injected subcutaneouosly with 8226 cells (3 × 107) in RPMI medium along with Matrigel matrix. Following detection of tumor, mice were divided into two groups: the control group that received daily intraperitoneal injection of vehicle (PBS) and the treatment group that received daily intraperitoneal injection of PRIMA-1Met (100 mg/kg). A, tumors were measured in two perpendicular dimensions every alternate day and tumor volumes were calculated (*, P < 0.05). B, survival was evaluated from the first day of treatment until death or an event occurred by using the Kaplan–Meier curve (P = 0.007). C, body weight was measured every alternate day till day 15. D, tumors were isolated from PRIMA-1-Met–treated and control mice and harvested for analysis by Western blot analysis for the expression of p73 and caspase-3. E, immunohistochemical analysis of tumor sections showed that treatment of mice bearing multiple myeloma tumors with PRIMA-1Met resulted in decrease in the proliferation index (Ki-67) and increase in the apoptotic index (TUNEL), further verifying the ability of PRIMA-1Met to induce apoptosis in multiple myeloma cells in vivo. Manujendra N. Saha et al. Mol Cancer Ther 2013;12:2331-2341 ©2013 by American Association for Cancer Research